Adaptive therapy dosing schedule in the investigational arm (arm 2)
| Investigational arm: adaptive therapy (three weekly carboplatin) | |
| Starting dose and maximum dose | AUC5 (based on NM GFR) |
| ≤25% change in CA125 | Repeat same dose |
| >25% decrease in CA125, but not reaching ≤10% baseline or ≤ULN (compared with start of preceding cycle) | Decrease dose by 1 AUC |
| >25% increase in CA125 (compared with start of preceding cycle) | Increase dose by 1 AUC (max AUC 5) |
| CA125 decrease to ≤10% baseline or to ≤ULN | Omit dose and repeat CA125 in 3 weeks |
| Restarting treatment after dose omission | AUC2 |
AUC, area under the curve; NM GFR, nuclear medicine glomerular filtration rate ; ULN, upper limit of normal.